Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002

Mark E Jones*1, Deborah C Draghi1, James A Karlowsky1, Daniel F Sahm1 and John S Bradley2

Address: 1Focus Technologies, Herndon, Virginia, USA 20171 and 2Childrens Hospital and Health Center, 3020 Children’s Way, San Diego, CA, USA 92123

Email: Mark E Jones* - mjones@focustechnologies.com; Deborah C Draghi - ddraghi@focustechnologies.com; James A Karlowsky - jkarlowsky@focustechnologies.com; Daniel F Sahm - dsahm@focustechnologies.com; John S Bradley - jbradley@chsd.org

* Corresponding author

Abstract

Background: Bacterial infections of the central nervous system, especially acute infections such as bacterial meningitis require immediate, invariably empiric antibiotic therapy. The widespread emergence of resistance among bacterial species is a cause for concern. Current antibacterial susceptibility data among central nervous system (CNS) pathogens is important to define current prevalence of resistance.

Methods: Antimicrobial susceptibility of pathogens isolated from CNS specimens was analyzed using The Surveillance Database (TSN®) USA Database which gathers routine antibiotic susceptibility data from >300 US hospital laboratories. A total of 6029 organisms derived from CNS specimen sources during 2000–2002, were isolated and susceptibility tested.

Results: Staphylococcus aureus (23.7%) and Streptococcus pneumoniae (11.0%) were the most common gram-positive pathogens. Gram-negative species comprised approximately 25% of isolates. The modal patient age was 1 or <1 year for most organisms. Prevalence of MRSA among S. aureus from cerebrospinal fluid (CSF) and brain abscesses were 29.9–32.9%. Penicillin resistance rates were 16.6% for S. pneumoniae, 5.3% for viridans group streptococci, and 0% for S. agalactiae. For CSF isolates, ceftriaxone resistance was S. pneumoniae (3.5%), E. coli (0.6%), Klebsiella pneumoniae (2.8%), Serratia marcescens (5.6%), Enterobacter cloacae (25.0%), Haemophilus influenzae (0%). Listeria monocytogenes and N. meningitidis are not routinely susceptibility tested.

Conclusions: Resistance is commonly detected, albeit still at relatively low levels for key drugs classes such as third-generation cephalosporins. This data demonstrates the need to consider predominant resistance phenotypes when choosing empiric therapies to treat CNS infections.
Background
Infections of the central nervous system (CNS) are potentially life threatening, requiring rapid diagnosis and immediate parenteral treatment. Nearly one in four adults with acute bacterial meningitis will die and many survivors sustain neurological deficits. Patient outcomes have not changed since the early 1960s, despite the introduction of potent antibiotics and specialized intensive care units [1]. Many infectious agents reach the CNS by hematogenous spread [2]. Pneumococcal infection may also arise from chronic infection of the paranasal sinuses and or middle ear. Furthermore, organisms present in the nasopharynx may reach the CNS directly, if the dura mater is damaged in some way following head injury or surgery [2]. Bacterial pathogens isolated from the CNS in patients with symptoms and diagnostic signs of bacterial meningitis are Streptococcus pneumoniae, Streptococcus agalactiae and other gram-positive cocci, Haemophilus influenzae, Neisseria meningitidis, and Escherichia coli [3,4]. The epidemiology of infectious agent varies with patient age and history of immunization against Haemophilus influenzae type b, meningococcus and pneumococcus. N. meningitidis is now the most common cause of meningitis in young people with a peak incidence at 6 months age coinciding with the loss of maternal antibody protection [5], whilst pneumococcal meningitis is the most common bacterial meningitis in middle-aged and elderly patients [3,4].

The need to treat infections of the CNS immediately requires empiric choice of an antibacterial agent. For many years β-lactams have comprised the cornerstone of therapy and parenteral third-generation cephalosporins such as ceftriaxone or cefotaxime are most commonly used [6]. Where infection is likely to have occurred from another body site, available laboratory information on identification and antibiogram of the organism can help target therapy appropriately. The emergence of antibiotic resistance in S. pneumoniae, Staphylococcus aureus, and enteric gram-negative bacilli documents the need for susceptibility testing to ensure appropriate antimicrobial chemotherapy. In contrast to community respiratory infections, for which antimicrobial susceptibility surveillance studies are frequently published, few data are available to provide a current perspective on the relative incidence and antibiotic susceptibility profiles bacterial pathogens isolated from CNS clinical specimens. In the routine clinical laboratory the majority of bacterial pathogens identified and tested are derived from the cerebrospinal fluid (CSF), most likely from patients with meningitis, and less commonly from brain abscesses, epidural abscesses or shunt/devices.

This study was undertaken to provide a current picture of bacterial pathogens commonly isolated from CSF and other CNS specimens by hospital laboratories participating in The Surveillance Network (TSN) Database USA during 2000–2002.

Methods
TSN hospital laboratory and antimicrobial susceptibility testing methodology
TSN Database comprises a network of hospital laboratories throughout the USA. The number of participant hospitals that susceptibility test bacterial isolates from CNS specimens was 154 (2000), 155 (2001), and 153 (2002). Susceptibility data are collected onsite by each participating laboratory as a part of their routine diagnostic susceptibility testing. Methods used by these laboratories include predominantly VITEK (bioMérieux, St. Louis, MO) and MicroScan (Dade-Microscan, Sacramento, CA). TSN reflects current testing in participating laboratories and is the data reported to physicians from the respective laboratories. Only susceptibility data interpreted according to the recommendations established by the National Committee for Clinical Laboratory Standards (NCCLS) [7] are included in TSN. Bacterial isolates not tested for susceptibility to antimicrobial agents are not included in this database. In addition, TSN uses a series of quality-control filters (i.e., critical rule sets) to screen susceptibility test results for patterns indicative of testing error and removes suspect results from analysis for laboratory confirmation.

Bacterial species and antimicrobials tested
We included only data on bacteria isolated from CNS clinical specimens, which comprised mostly isolates from CSF (most likely from patients with meningitis), but also isolates from brain abscesses, epidural abscess and shunt/devices. All specimens were isolated from patients during January 1, 2000 through December 31, 2002. Data were analyzed to determine the relative incidence and susceptibility to a core set of antimicrobial agents relevant to the treatment of CNS infections, as tested by participant clinical laboratories. For each organism only antibiotics for which susceptibility data were available were listed. Thus, drugs listed vary per organism. No susceptibility data for colistin for gram-negative organisms were available through TSN. MICs were interpreted as susceptible, intermediate, or resistant in TSN according to 2003 breakpoint criteria defined by the NCCLS [8]. TSN was not able to distinguish between community-acquired or hospital-acquired infection. In addition, TSN was not able to determine whether some isolates for which susceptibility data were requested, were actually contaminants and not true pathogens. Data available through TSN did not allow the identification of H. influenzae as encapsulated or as type b strains. No NCCLS interpretive breakpoints were defined for N. meningitides, so few laboratories susceptibility test this organism.
Results

During the 3-year time period considered, a total of 6029 organisms were isolated and susceptibility tested (Table 1). More than 90% of all organisms were derived from CSF, the remainder from brain or epidural abscess or shunt/device infections. The most common gram-positive isolates were Staphylococcus aureus (23.7%), Streptococcus pneumoniae (11.0%), viridans group streptococci (VGS) (10.2%), and Enterococcus species (9.8%). Staphylococcus agalactiae (2.2%), coagulase-negative staphylococci (shunt/device infections only) (3.1%), Propionibacterium acnes (2.0%) and Neisseria meningitidis (1.0%) were comparatively rare.

E. coli (5.0%), Enterobacter cloacae (4.3%), Klebsiella pneumoniae (2.5%) and S. marcescens (2.1%) were the most common Enterobacteriaceae. Pseudomonas aeruginosa (4.9%) was equally as common as E. coli. Although N. meningitidis comprised just 60/6029 isolates during the 3-year period the organism was likely under-represented because organisms included in this study were only those accompanied by a susceptibility test result. The modal age of patients was 1 or <1 year for all organisms except for P. acnes (33 years), N. meningitidis (2 years) and Corynebacterium spp. (16 years). H. influenzae was rare. For enteric bacilli, staphylococcal, P. aeruginosa and Acinetobacter spp. a second smaller incidence peak, primarily with isolates derived from shunt infections and from CSF, was detected for patients >65 years (data not shown).

Susceptibility of coagulase-positive or -negative staphylococcal species (shunt isolates only) was shown (Table 2). S. aureus was the most common pathogen tested at all sites of infection. The proportion of S. aureus testing as MRSA using oxacillin as marker was 29.9%, 32.9%, 15.5% and 16.7% from CSF, brain abscess, shunt/device related or epidural abscess specimen sources, respectively. For coagulase-negative staphylococci 67.2% of isolates were oxacillin-resistant. Overall for all organisms, shunt isolates comprised <2.0% of all isolates isolated and tested from CNS sources during this time period, comprising mainly staphylococcal species. Parenteral cephalosporins were not active against MRSA but generally active against >99% of oxacillin-susceptible isolates based on NCCLS breakpoints for non-CNS infections. All staphylococci were vancomycin susceptible. Low levels of resistance to gentamicin, chloramphenicol, trimethoprim-sulfamethoxazole and rifampin were detected, although resistance tended to be higher among coagulase-negative staphylococci.

Table 3 shows susceptibility for the other most common gram-positive organisms derived from CSF. VGS were isolated in significant numbers only from brain abscesses. For isolates from CSF specimens, resistance among enterococci varied by species. The prevalence of vancomycin resistance among E. faecium was 61.5% and the prevalence of resistance to ampicillin, the class representative
for amino-penicillins, was 84.9%. Significantly less resistance was detected among \textit{E. faecalis} isolates. Ceftriaxone resistance rates were recorded in 9.1% of \textit{VGS}, 3.5% of \textit{S. pneumoniae}, and 0% of \textit{S. agalactiae} (data not tabulated), although more active than cefotaxime. Penicillin resistance was recorded in 5.3% of \textit{VGS}, 16.6% of \textit{S. pneumoniae}, and 0% of \textit{S. agalactiae} (data not tabulated). For \textit{S. pneumoniae} meropenem resistance was recorded in 7.9% of isolates but was not detected in other streptococcal species. Resistance to chloramphenicol among streptococci was uncommon (3–3.9%). Rifampin resistance ranged from 17.2% to 30.0% among enterococci and was not recorded among \textit{S. pneumoniae}. Resistance in \textit{VGS} from brain abscesses to ceftriaxone and penicillin was recorded as 3.0% and 1.4%, respectively, with organisms generally more susceptible than those isolated from CSF specimens. With the exception of a small number of \textit{VGS} from CSF specimens, all streptococci were susceptible to levofloxacin.

Susceptibility of predominant gram-negative species isolated from CSF specimens was shown (Table 4). Gram-negative isolates were rarely isolated from brain abscess, shunt, or epidural abscess specimens. No meropenem resistance was detected in \textit{Enterobacteriaceae} but detected in 10.3% and 23.5% of \textit{P. aeruginosa} and \textit{A. baumannii}.

Resistance to amikacin was rare among \textit{Enterobacteriaceae} and was 4.9% for \textit{P. aeruginosa} and 17.9% for \textit{Acinetobacter} spp. Among enteric organisms the prevalence of resistance was low against ceftriaxone for \textit{E. coli} (0.6%), \textit{E. aerogenes} (1.6%), and \textit{K. pneumoniae} (2.8%) and were higher for \textit{S. marcescens} (5.6%), \textit{K. oxytoca} (13.3%), and \textit{E. cloacae} (25.0%). Resistance to ceftazidime was 1.4% and 18.0% in \textit{E. coli} and \textit{K. pneumoniae}, respectively. For \textit{Enterobacteriaceae}, aztreonam resistance ranged from 1.5% in \textit{E. coli} to 26.5% in \textit{E. cloacae}. Levofloxacin resistance rates were uncommon in all \textit{Enterobacteriaceae} tested apart from \textit{K. pneumoniae} (9.2%). For \textit{P. aeruginosa} the prevalence of ceftazidime and amikacin resistance was 11.0% and 4.9%, respectively and for \textit{A. baumannii} 38.7% and 17.9%, respectively. For both of these organisms relatively high resistance to levofloxacin was detected and meropenem was the most active \(\beta\)-lactam compound tested with resistance recorded as 10.3% and 23.5%, respectively. Approximately 24.0% of \textit{H. influenzae} produced \(\beta\)-lactamase as estimated by ampicillin resistance. All \textit{H. influenzae} isolates tested were susceptible to cefotaxime, ceftriaxone, and levofloxacin.

**Discussion**

Vaccination against infections with \textit{H. influenzae} and \textit{N. meningitidis} has significantly reduced the incidence of community-acquired infections caused by these organ-

---

**Table 2: Susceptibility of staphylococcal species isolated from cerebrospinal fluid, brain abscess, shunt related and epidural specimen sources. TSN Database USA 2000–2002.**

| Organism             | Antimicrobial | Cerebrospinal fluid | Brain abscess | Shunt related | Epidural abscess |
|----------------------|---------------|---------------------|---------------|---------------|-----------------|
|                      | Total n  | %S      | %R      | Total n  | %S      | %R      | Total n  | %S      | %R      | Total n  | %S      | %R      |
| \textit{Staphylococcus aureus} | cefotaxime | 270      | 74.8    | 25.2    | 12      | 75.0    | 25.0    | 10      | 90.0    | 10.0    | NA      | NA      | NA      |
|                      | ceftriaxone  | 273      | 71.8    | 27.8    | 13      | 76.9    | 23.1    | 18      | 88.9    | 11.1    | NA      | NA      | NA      |
|                      | levofloxacin | 666      | 73.1    | 22.8    | 48      | 72.9    | 27.1    | 33      | 97.0    | 3.0     | 83      | 79.5    | 18.1    |
|                      | chloramphenicol | 277      | 95.3    | 4.7     | 6       | 100.0   | 0       | 9       | 88.9    | 11.1    | NA      | NA      | NA      |
|                      | gentamicin   | 941      | 93.0    | 7.0     | 65      | 93.8    | 6.2     | 53      | 94.3    | 5.7     | 38      | 97.4    | 2.6     |
|                      | oxacillin    | 1189     | 70.1    | 29.9    | 76      | 67.1    | 32.9    | 71      | 84.5    | 15.5    | 108     | 83.3    | 16.7    |
|                      | rifampin     | 851      | 96.9    | 3.1     | 51      | 100.0   | 0       | 48      | 91.7    | 8.3     | 24      | 100.0   | 0       |
|                      | TMP-SMXc     | 1058     | 95.9    | 4.1     | 72      | 94.4    | 5.6     | 47      | 100.0   | 0       | 101     | 96.0    | 4.0     |
|                      | vancomycin   | 1150     | 100.0   | 0       | 76      | 100.0   | 0       | 58      | 100.0   | 0       | 102     | 100.0   | 0       |
|                      | cefotaxime   | NDd      | ND      | ND      | ND      | ND      | ND      | 32      | 34.4    | 65.6    | ND      | ND      | ND      |

**Notes:**
- NCCLS interpretation for susceptible (S) and resistant (R) according to NCCLS guidelines [8]
- NA – <5 organisms tested
- TMP-SMX – Trimethoprim-sulfamethoxazole
- ND – No data
isms [9,10]. Additionally, the growing use of the pneumococcal conjugate vaccine has also had a positive impact on the incidence of pneumococcal meningitis [11,12]. Since clinicians will likely initiate antimicrobial therapy prior to the microbiological characterization of the infecting agent, with the reduction in incidence of some species and increased resistance in others, resistance surveillance plays an important role in helping to understand trends in predominant pathogens and the impact of resistance on empiric choice [13]. The TSN database was not able to discriminate between specific diagnoses; however, considering bacterial pathogens isolated from specific specimen sources provides a contemporary picture of current susceptibility to commonly considered antimicrobial agents for the most prevalent organisms encountered at these sites of infections.

For the most significant community-acquired pathogens, this study showed similarities between epidemiological trends recently published. For meningitis in the USA, a report by Schuchat et al., 1997, recorded a significant shift from 15 months to 25 years, in the median age of patients with meningitis due to the five major pathogens: H. influenzae, S. pneumoniae, N. meningitidis, S. agalactiae, and L. monocytogenes [3]. Overall including all specimen sources together, although the majority of isolates were derived from the CSF, our study showed that isolates were derived from a wide spectrum of patient ages. However with few exceptions, the modal age of patients was ≤1 year old, demonstrating the burden of infection to be with infants and with a second peak for patients >65 years [3].

### Table 3: Susceptibility of gram-positive organisms isolated from cerebrospinal fluid and brain abscess specimen sources. TSN Database USA 2000–2002.

| Organism            | Antimicrobial | Cerebrospinal fluid | Brain abscess |
|---------------------|---------------|---------------------|---------------|
|                     | Total n | %S | %R | Total n | %S | %R |
| **Enterococcus faecalis** |         |     |     |         |     |     |
| ampicillin          | 229     | 98.7 | 1.3 | NDb   | ND   | ND |
| chloramphenicol     | 79      | 79.7 | 15.2 | ND   | ND   | ND |
| levofloxacin        | 136     | 81.6 | 18.4 | ND   | ND   | ND |
| penicillin          | 165     | 99.4 | 0.6 | ND   | ND   | ND |
| rifampin            | 58      | 58.6 | 17.2 | ND   | ND   | ND |
| vancomycin          | 239     | 98.7 | 1.3 | ND   | ND   | ND |
| **Enterococcus faecium** |         |     |     |         |     |     |
| ampicillin          | 93      | 15.1 | 84.9 | ND   | ND   | ND |
| chloramphenicol     | 54      | 92.6 | 0   | ND   | ND   | ND |
| levofloxacin        | 56      | 12.5 | 85.7 | ND   | ND   | ND |
| penicillin          | 50      | 22.0 | 78.0 | ND   | ND   | ND |
| rifampin            | 30      | 56.7 | 30.0 | ND   | ND   | ND |
| vancomycin          | 96      | 38.5 | 61.5 | ND   | ND   | ND |
| **Viridans group Streptococci** |     |     |     |         |     |     |
| ampicillin          | 95      | 62.1 | 6.3 | 10 | 90.0 | 0 |
| **Streptococcus pneumoniae** |     |     |     |         |     |     |
| cefotaxime          | 174     | 85.1 | 9.8 | 32 | 96.9 | 3.1 |
| ceftriazone         | 220     | 87.3 | 9.1 | 33 | 93.9 | 3.0 |
| chloramphenicol     | 100     | 96.0 | 3.0 | 14 | 92.9 | 0 |
| meropenem           | 19      | 100  | 0   | 13 | 100  | 0 |
| levofloxacin        | 90      | 96.7 | 3.3 | 24 | 100  | 0 |
| penicillin          | 437     | 63.2 | 36.8 | 72 | 97.2 | 2.8 |
| vancomycin          | 396     | 100  | 0   | 44 | 100  | 0 |
| cefotaxime          | 313     | 80.5 | 19.5 | ND | ND   | ND |
| ceftriazone         | 404     | 85.4 | 3.5 | ND | ND   | ND |
| chloramphenicol     | 180     | 96.1 | 3.9 | ND | ND   | ND |
| meropenem           | 76      | 78.9 | 21.1 | ND | ND   | ND |
| levofloxacin        | 283     | 100  | 0   | ND | ND   | ND |
| penicillin          | 565     | 59.5 | 40.5 | ND | ND   | ND |
| rifampin            | 70      | 100  | 0   | ND | ND   | ND |
| TMP-SMXd            | 233     | 65.2 | 34.8 | ND | ND   | ND |
| vancomycin          | 453     | 100  | -   | ND | ND   | ND |

aNCCLS interpretation for susceptible (S) and resistant (R) according to NCCLS guidelines [8]; bND – No data; cNS – Percent non-susceptible (including intermediate and resistant isolates); dTMP-SMX – Trimethoprim-sulfamethoxazole; eDashed line indicates that NCCLS breakpoints do not currently exist to interpret results as resistant.
Table 4: Susceptibility of gram-negative organisms isolated from cerebrospinal fluid specimen sources. TSN Database USA 2000–2002

| Organism             | Antimicrobial | Total n | %S | %R |
|----------------------|---------------|---------|----|----|
| *Escherichia coli*   | amikacin      | 164     | 98.8 | 0  |
|                      | ampicillin    | 267     | 44.2 | 54.7 |
|                      | aztreonam     | 137     | 96.4 | 1.5 |
|                      | cefotaxime    | 168     | 98.2 | 0  |
|                      | ceftazidime   | 210     | 98.1 | 1.4 |
|                      | ceftriaxone   | 180     | 97.8 | 0.6 |
|                      | gentamicin    | 260     | 93.5 | 5.4 |
|                      | levofloxacin  | 198     | 97.5 | 2.5 |
|                      | meropenem     | 76      | 100  | 0  |
|                      | piperacillin  | 188     | 50.0 | 38.8 |
|                      | TMP-SMX       | 252     | 77.0 | 23.0 |
| *Pseudomonas aeruginosa* | amikacin    | 184     | 92.9 | 4.9 |
|                      | aztreonam     | 133     | 67.7 | 15.0 |
|                      | cefotaxime    | 111     | 9.0  | 49.5 |
|                      | ceftazidime   | 236     | 80.1 | 11.0 |
|                      | ceftriaxone   | 116     | 6.0  | 61.2 |
|                      | gentamicin    | 251     | 80.9 | 11.2 |
|                      | levofloxacin  | 174     | 82.2 | 11.5 |
|                      | meropenem     | 97      | 84.5 | 10.3 |
|                      | piperacillin  | 198     | 82.8 | 17.2 |
|                      | TMP-SMX       | 128     | 0.8  | 99.2 |
| *Enterobacter cloacae* | amikacin    | 160     | 98.8 | 0  |
|                      | ampicillin    | 229     | 2.2  | 91.7 |
|                      | aztreonam     | 147     | 65.3 | 26.5 |
|                      | cefotaxime    | 154     | 63.6 | 28.6 |
|                      | ceftazidime   | 196     | 67.3 | 29.6 |
|                      | ceftriaxone   | 184     | 70.7 | 25.0 |
|                      | gentamicin    | 227     | 95.2 | 4.8 |
|                      | levofloxacin  | 176     | 96.0 | 4.0 |
|                      | meropenem     | 79      | 100  | 0  |
|                      | piperacillin  | 168     | 64.9 | 28.0 |
|                      | TMP-SMX       | 220     | 93.2 | 6.8 |
| *Acinetobacter baumannii* | amikacin    | 112     | 75.0 | 17.9 |
|                      | aztreonam     | 88      | 8.0  | 73.9 |
|                      | cefotaxime    | 102     | 21.6 | 54.9 |
|                      | ceftazidime   | 142     | 48.6 | 38.7 |
|                      | ceftriaxone   | 119     | 25.2 | 53.8 |
|                      | gentamicin    | 143     | 61.5 | 38.5 |
|                      | levofloxacin  | 106     | 53.8 | 43.4 |
|                      | meropenem     | 68      | 75.0 | 23.5 |
|                      | piperacillin  | 111     | 40.5 | 40.5 |
|                      | TMP-SMX       | 140     | 54.3 | 45.7 |
| *Klebsiella pneumoniae* | amikacin    | 95      | 92.6 | 0  |
|                      | ampicillin    | 129     | 0    | 98.4 |
|                      | aztreonam     | 70      | 84.3 | 14.3 |
|                      | cefotaxime    | 94      | 87.2 | 3.2 |
|                      | ceftazidime   | 111     | 76.6 | 18.0 |
|                      | ceftriaxone   | 108     | 84.3 | 2.8 |
|                      | gentamicin    | 131     | 87.8 | 8.4 |
|                      | levofloxacin  | 98      | 88.8 | 9.2 |
|                      | meropenem     | 47      | 100  | 0  |
|                      | piperacillin  | 102     | 65.7 | 26.5 |
|                      | TMP-SMX       | 133     | 83.5 | 16.5 |
| *Serratia marcescens* | amikacin      | 71      | 95.8 | 2.8 |
|                      | ampicillin    | 104     | 5.8  | 92.3 |
|                      | aztreonam     | 55      | 87.3 | 7.3 |
|                      | cefotaxime    | 70      | 80.0 | 8.6 |
|                      | ceftazidime   | 86      | 93.0 | 4.7 |
|                      | ceftriaxone   | 71      | 91.5 | 5.6 |
The low comparative prevalence of *H. influenzae* indicates the success of the Hib vaccination program, which has largely removed this organism from its once ubiquitous role in meningeal infection in children in the United States [14]. Schuchat et al. also reported *L. monocytogenes* to be associated with infections in children <1 year old and increases in incidence in patients older than 65 years. In this current study, the relative importance of both *L. monocytogenes* and *N. meningitidis* in infection cannot be measured since the organisms were rarely tested for antimicrobial susceptibilities in hospital laboratories and thus not reported through the system. Additionally, no NCCLS breakpoints have been defined for *N. meningitidis* [9]. Invasive pneumococcal disease is a significant cause of morbidity and mortality in the USA, especially for the young and old. Schuchat et al. demonstrated *S. pneumoniae* to infect patients of all ages, the same trend observed in our study. We also showed that with the exception of staphylococci, *S. pneumoniae* was the most common pathogen reported. A previous report showed 4.4% of cases of invasive pneumococcal disease associated with meningitis [3]. Further analysis of TSN showed that during the study period laboratories reported 661 non-repeat CNS pneumococcal isolates and 9868 non-repeat pneumococcal blood isolates, corresponding to a 6–7% rate of patients with invasive infections likely to be associated with pneumococcal meningitis, close to the 4–5% reported in 1995 [3]. This study also showed *Enterobacteriaceae* to be more common in hospital-acquired meningeal infections. *S. aureus* was by far the most frequently encountered pathogen in participant hospital laboratories, in this study together comprising 23.7% of isolates and the only isolate encountered at all specimen source sites considered. A previous French study showed *S. aureus* to be the most common pathogen associated with neurosurgical infections [15]. In addition to the staphylococci, *Enterococcus* spp., *P. aeruginosa*, *P. acnes*, and *Enterobacteriaceae* were most commonly isolated from infants (<1 year old), although the median age also demonstrates the common involvement in adult patients. Together these organisms

| Table 4: Susceptibility of gram-negative organisms isolated from cerebrospinal fluid specimen sources. TSN Database USA 2000–2002 |
|---------------------------------------------------------------|
| **gentamicin** | 108 | 95.4 | 2.8 |
| **levofloxacin** | 80 | 98.8 | 1.3 |
| **meropenem** | 43 | 100 | 0 |
| **piperacillin** | 81 | 72.8 | 21.0 |
| **TMP-SMX** | 105 | 95.2 | 4.8 |
| **Enterobacter aerogenes** |
| **amikacin** | 60 | 100 | 0 |
| **ampicillin** | 87 | 5.7 | 87.4 |
| **aztreonam** | 42 | 73.8 | 11.9 |
| **cefotaxime** | 54 | 74.1 | 1.9 |
| **ceftazidime** | 78 | 73.1 | 17.9 |
| **ceftriaxone** | 63 | 84.1 | 1.6 |
| **gentamicin** | 81 | 100 | 0 |
| **levofloxacin** | 51 | 100 | 0 |
| **meropenem** | 22 | 100 | 0 |
| **piperacillin** | 64 | 68.8 | 14.1 |
| **TMP-SMX** | 85 | 100 | 0 |
| **Haemophilus influenzae** |
| **ampicillin** | 61 | 72.1 | 24.6 |
| **cefotaxime** | 27 | 100 | 0 |
| **ceftazidime** | NA | NA | NA |
| **ceftriaxone** | 54 | 100 | 0 |
| **levofloxacin** | 10 | 100 | 0 |
| **TMP-SMX** | 32 | 87.5 | 9.4 |
| **Klebsiella oxytoca** |
| **amikacin** | 37 | 100 | 0 |
| **ampicillin** | 52 | 3.8 | 86.5 |
| **aztreonam** | 34 | 76.5 | 17.6 |
| **cefotaxime** | 37 | 81.1 | 16.2 |
| **ceftazidime** | 44 | 81.8 | 18.2 |
| **ceftriaxone** | 45 | 84.4 | 13.3 |
| **gentamicin** | 51 | 96.1 | 3.9 |
| **levofloxacin** | 39 | 100 | 0 |
| **meropenem** | 23 | 100 | 0 |
| **piperacillin** | 38 | 73.7 | 21.1 |
| **TMP-SMX** | 51 | 80.4 | 19.6 |

*NCCLS interpretation for susceptible (S) and resistant (R) according to NCCLS guidelines [8]*

- **TMP-SMX** – Trimethoprim-sulfamethoxazole
- **NA** – <5 organisms tested
- **d** – Dashed line indicates that NCCLS breakpoints do not currently exist to interpret results as resistant
are becoming common causes of meningeal infection, often as a complication in immunocompromised patients, in patients with septicemia, following head trauma, or surgical procedures especially those involving CSF shunts.

The relatively high incidence of oxacillin-resistant S. aureus from CSF and brain abscesses negatively impacts the empiric utility of isoxazolyl penicillins reaffirming the need to include anti-MRSA coverage for patients with meningitis and brain abscesses, unless subsequent susceptibility testing shows the organism to be oxacillin susceptible. Even among isolates from shunts and epidural abscesses the 15–17% incidence of oxacillin resistance likely mandates the use of empiric therapies such as vancomycin that cover MRSA. However, it is important to note that these levels are lower than the national rates of MRSA of 51.2% (36,181/70,693) recorded among the general inpatient population in the USA during 2002 [TSN Database USA, Focus Technologies Inc. Data on file]. Susceptibility test results for MRSA to linezolid, a recently FDA-approved oxazolidinone-class antibiotic, and daptomycin, a recently approved glycopeptide-class antibiotic, were not available at the time of this study, although neither drugs have indications to treat infections of the central nervous system. Interestingly, despite an overall increase in the incidence of MRSA in hospitals in recent years in both inpatient and outpatient environments [16] an increased incidence of multi-drug susceptible MRSA, especially in community infections, has also been reported [17], which may augment the use of other compounds such as clindamycin in therapy. For shunt/device related infections, the high rates of oxacillin resistance recorded among coagulase-negative staphylococci indicate the need to consider appropriate therapies to cover these phenotypes. For both staphyloccocal species resistance to rifampin, occasionally used in combination, was rare, comprising 0–6.5% of isolates from each species, respectively. Despite reports of vancomycin resistance in coagulase-negative staphylococci [18] and more recently S. aureus [19,20], during the three-year study period, no vancomycin non-susceptible isolates of either species were recorded. Vancomycin also plays an important role in the treatment of other resistant gram-positive infections, most importantly those caused by penicillin-resistant S. pneumoniae (penicillin MIC >2 µg/ml), for which no resistance was documented. Of the 661 isolates reported during the study period (11.0% of total), 16.6% and 23.9% tested as penicillin-resistant and -intermediate, respectively. For meningitis caused by pneumococci and in situations where the incidence of penicillin resistance is significant, the use of third-generation, parenteral cephalosporins such as ceftriaxone or cefotaxime is a more suitable empiric therapy. The percentage resistance to third-generation cephalosporins for the common streptococcal isolates from CSF, likely involved in meningeal infection, remained low (3.5% for ceftriaxone); however, concerns about resistance in CNS infections are sufficient to prompt recommendations to combine ceftriaxone or cefotaxime with vancomycin for empiric therapy of pneumococcal CNS infections. The reported rate of resistance in S. pneumoniae to ceftriaxone and cefotaxime reflects the higher breakpoints used compared to those used for non-meningeal pneumococcal isolates, reflecting the lower antibiotic concentrations achievable in the CNS. Importantly in addition to streptococci, 100% of H. influenzae tested as susceptible to ceftriaxone and cefotaxime. As such the utility of this drug class in community or hospital acquired infections meningeal infections with these organisms remains unchanged.

The incidence of vancomycin-resistant phenotypes among enterococci, organisms not commonly associated with meningeal infections, is alarming if the organisms isolated were colonizers. Importantly, the majority of glycopeptide-resistant isolates are E. faecalis, which are less common than E. faecium.

Our study showed resistance to amikacin remained very low (0–2.8%) among Enterobacteriaceae and low among Acinetobacter spp. and P. aeruginosa (17.9% and 4.9%, respectively), although the utility of this agent is limited in CNS infections. Importantly, bearing in mind their role in empiric therapy for meningitis, resistance to third-generation cephalosporins such as ceftriaxone, remained very uncommon in the common enterobacterial species (E. coli 0.6%, K. pneumoniae 2.6%, and S. marcescens 5.2%). Resistance to ceftazidime in these species was somewhat higher than for ceftriaxone. Together these data suggest that the incidence of extended spectrum β-lactamases or AmpC β-lactamase producers still remains low, preventing a reliance on the use of carbapenems such as meropenem to which resistance among gram-negative organisms remains very rare. Changing patterns of antimicrobial resistance and the involvement of unusual species because of the increase in immunocompromised patients, has created renewed interest in drugs such as fluoroquinolones, which have previously been shown to have good potential for treating meningitis [21], although currently do not have an indication for use in CNS infection or in pediatrics. Nevertheless using levofloxacin as a marker for this drug class activity, streptococci, several species of Enterobacteriaceae and H. influenzae were highly susceptible using current breakpoint guidelines.

Conclusions
Several factors influence the choice of antibacterial agent in the treatment of bacterial meningitis. Perhaps most importantly is the degree at which the agent is able to penetrate into the CSF, which to a large extent depends on the
status of the blood brain barrier [22]. Low toxicity and rapid bactericidal activity are also important factors to consider and for these reasons β-lactams have always played a key role in treating infections of the CNS. Our study showed that for the treatment of the most important pathogens associated with acute community-acquired meningitis including S. pneumoniae, H. influenzae, and group B streptococci, while resistance to penicillin derivatives is relatively common, resistance to third-generation cephalosporins remains uncommon. Similarly, third-generation cephalosporins also retain good activity against the most common species of Enterobacteriaceae. For infections in which oxacillin-resistant staphylococcal species are suspected or shown microbiologically, vancomycin remains as a frontline agent to which no resistant isolates were detected through 2002. While national surveillance studies such as this are able to detect general trends in susceptibility, this information combined with local institutional level data play a critical role in choosing empiric therapies.

Authors’ contributions
MI conceived the study, provided data interpretation and drafted the manuscript. DD analyzed the study data; JK and DS provided expert microbiological analysis and interpretation of study data; JB provided clinical expertise in interpretation of data and drafting manuscript. All authors read and approved the final manuscript.

Acknowledgments
We thank F. Hoffmann-La Roche Ltd., Basel, Switzerland for financial support of this study. Additionally, we thank the many US clinical microbiology laboratories that contribute data to TSN Databases, without whom such studies would not be possible.

References
1. Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS Jr, Swartz MN. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993, 328:21-28.
2. Tunkel RA, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Clin Micro Rev 1993, 6:118-136.
3. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, Lefkowitz L, Perkins BA. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med. 1997, 337:970-976.
4. Davison KL, Ramsay ME. The epidemiology of acute meningitis in children in England and Wales. Arch Dis Child 2003, 88:662-664.
5. Shepard CW, Rosenstein NE, Fischer M, and the Active Bacterial Core Surveillance Team: Neutonal meningococcal disease in the United States, 1990 to 1999. Pediatr Infect Dis J 2003, 22:418-422.
6. Aronson SI. Bacterial Meningitis: Principles and Practical Aspects of Therapy. Curr Infect Dis Rep 2000, 2:337-344.
7. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial tests for bacteria that grow aerobically, M7-A6. National Committee for Clinical Laboratory Standards Wayne, PA: 2003.
8. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing; tenth informational supplement, M100-S12. National Committee for Clinical Laboratory Standards Wayne, PA: 2002.
9. Caccioli S, Hightower AV. Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine: A cost-effectiveness model of strategy assessment. JAMA 1985, 255:521-529.
10. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis 1999, 180:1894-1901.
11. Whitney CG. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65. Genomics 2003, 58:20-22.
12. Darkes MJ, Bosker GL. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr Drugs 2002, 4:609-630.
13. Hoffman JA, Mason EO, Schutze GE, Tan TQ, Barson WJ, Ginver LB, Wald ER, Bradley JS, Yoge v R, Kaplan SL. Streptococcus pneumoniae infections in the neonate. Pediatrics 2003, 112:10-102.
14. Adams WG, Deaver KA, Cochli SL, Pikatias BD, Zell ER, Broome CV, Wenger JD. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993, 269:221-226.
15. Korinek AM. Risk factors for neurosurgical site infections after craniotomy: a prospective multicenter study of 2944 patients. The French Study Group of Neurosurgical Infections, the SEHP, and the C-CLIN Paris-Nord. Service Epidemiologie Hygiene et Prevention. Neurosurgery 1997, 41:1073-1079. discussion 1079-81.
16. Jones ME, Mayfield DC, Thornberry C, Karlowsky JA, Sahn DF, Peterson D. Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000. Antimicrob Agents Chemother 2002, 46:3104-3105.
17. Martinez-Aguilar G, Hamme rman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003, 22:593-598.
18. Schwalbe RS, Stapleton JT, Gilligan PH. The emergence of vancomycin resistance in coagulase negative staphylococci. N Engl J Med 1987, 316:927-931.
19. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chem 1997, 40:135-136.
20. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GA, Brown WJ, Cardo D, Fridkin SK. Vancomycin-resistant Staphylococcus aureus Investigative Team: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003, 348:1342-1347.
21. Saez-Llorens X, McCoig C, Feri s JM, Vargas SL, Klugman KP, Hussey VS Jr, Swartz MN: Neonatal meningococcal disease in the United States, 1992–1996. J Infect Dis 1999, 180:1894-1901.
22. Whitney CG. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65. Genomics 2003, 58:20-22.
12. Darkes MJ, Bosker GL. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr Drugs 2002, 4:609-630.
13. Hoffman JA, Mason EO, Schutze GE, Tan TQ, Barson WJ, Ginver LB, Wald ER, Bradley JS, Yoge v R, Kaplan SL. Streptococcus pneumoniae infections in the neonate. Pediatrics 2003, 112:10-102.
14. Adams WG, Deaver KA, Cochli SL, Pikatias BD, Zell ER, Broome CV, Wenger JD. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993, 269:221-226.
15. Korinek AM. Risk factors for neurosurgical site infections after craniotomy: a prospective multicenter study of 2944 patients. The French Study Group of Neurosurgical Infections, the SEHP, and the C-CLIN Paris-Nord. Service Epidemiologie Hygiene et Prevention. Neurosurgery 1997, 41:1073-1079. discussion 1079-81.
16. Jones ME, Mayfield DC, Thornberry C, Karlowsky JA, Sahn DF, Peterson D. Prevalence of oxacillin resistance in Staphylococcus aureus among inpatients and outpatients in the United States during 2000. Antimicrob Agents Chemother 2002, 46:3104-3105.
17. Martinez-Aguilar G, Hamme rman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003, 22:593-598.
18. Schwalbe RS, Stapleton JT, Gilligan PH. The emergence of vancomycin resistance in coagulase negative staphylococci. N Engl J Med 1987, 316:927-931.
19. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chem 1997, 40:135-136.
20. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GA, Brown WJ, Cardo D, Fridkin SK. Vancomycin-resistant Staphylococcus aureus Investigative Team: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003, 348:1342-1347.
21. Saez-Llorens X, McCoig C, Feri s JM, Vargas SL, Klugman KP, Hussey VS Jr, Swartz MN: Neonatal meningococcal disease in the United States, 1992–1996. J Infect Dis 1999, 180:1894-1901.
22. Whitney CG. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65. Genomics 2003, 58:20-22.